Q&A With Mark Freedman From the University Ottawa: Longterm Studies of Aubagio Continue to Show Safety for Multiple Sclerosis Treatment

Video

With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.

With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.

Mark Freedman, HBSc, MSc, MD, CSPQ, from the University of Ottawa addressed the recent work on the treatment during ECTRIMS 2015 in Barcelona. Freedman noted that Aubagio has the distinction of being the only oral treatment for multiple sclerosis to not have any "major" safety issues present during its time.

Related Videos
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
© 2024 MJH Life Sciences

All rights reserved.